Zimbabwe has declined a major US health deal worth $367m (£272m) spanning five years due to Washington's insistence on confidential information.
This rejection was revealed after a official document from December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
An official spokesperson has since clarified that the US was demanding access to health data for research and profit while was unwilling to share the resulting advantages from future treatments.
"We must now begin the difficult and regrettable task of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had furnished over $1.9bn in health funding to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for more dialogue to find a deal acceptable to both sides so the country's vital HIV treatment initiative can be sustained.
Broader Implications
This rejection follows a comparable situation in neighbouring Kenya, where a high court blocked a related health funding agreement after legal challenges were filed about the security of Kenyans' medical information.
After returning to office last year, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
USAID had managed assistance for the American government, but Trump argued its spending was "wasteful" and his government was seeking direct bilateral deals to enhance transparency and responsibility.
As per reports, 16 African countries have so far signed these new agreements, representing more than $18.3bn in committed funds.
Specifics of the Declined Agreement
The funds for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this collaboration might have yielded significant advantages for Zimbabwean communities, particularly the 1.2 million currently on HIV treatment via US-supported programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"Our nation was requested to provide its biological resources and data indefinitely, with no corresponding promise of benefiting from any medical innovations – such as new medicines or tests – that could be developed from that shared data," his statement read.
"Effectively, our country would provide the basic resources for medical research with no certainty that the resulting innovations would be available to our population if a future disease outbreak arise."
National Interest and International Frameworks
Mangwana further noted that the American exit from the global health body and its push of bilateral health agreements were disrupting systems previously set up via the international health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing system created to manage future pandemics.
"This framework is intended to guarantee that when a nation provides its information, the benefits – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the funds to create them."
The government's concerns over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We encourage continued discussions with our US partners on how subsequent co-operation could be structured in a way that respects the sovereignty and interests of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the government's concerns, but suggested that talks need to persist considering much of the country's Aids initiatives were funded by international support.
"Where specific concerns exist, such as those relating to data governance or implementation frameworks, these can often be addressed through technical clarification and mutually agreed protections," the group said.
The halted deal emphasises the ongoing tensions between accepting crucial international aid and protecting a country's data in an ever more data-driven world.